Company: Precision BioSciences
Job title: CMO
Chris Heery, MD, is the Chief Medical Officer at Precision BioSciences where he has led the clinical program for allogeneic CAR T since its inception in 2019. Prior to joining Precision, Dr. Heery served as Chief Medical Officer of Bavarian Nordic where he oversaw clinical development programs for its immune-oncology and infectious diseases portfolios. Prior to this, he was Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at NCI. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also held an Adjunct Appointment in the Genitourinary Malignancies Branch. At NCI, Dr. Heery was part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. He is board certified in Medical Oncology and Internal Medicine and completed his internal medicine residency at the University of Illinois at Chicago after receiving his M.D. from East Carolina University Brody School of Medicine. Dr. Heery also holds a B.A. in English Literature from Duke University.
Learnings from Dose Level 1 & Dose Level 2 of the Phase 1 Trial of PBCAR0191, an Allogeneic CD19 CAR-T for the Treatment of Relapsed/Refractory NHL & ALL 10:00 am
day: Day Two